Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 11;15(1):1750.
doi: 10.1038/s41598-025-85339-x.

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy

Shigeo Ohba  1 , Takao Teranishi  2 , Kazuyasu Matsumura  2 , Masanobu Kumon  2 , Daijiro Kojima  2 , Eiji Fujiwara  2 , Kazutaka Nakao  2 , Kiyonori Kuwahara  2 , Kazuhiro Murayama  3 , Eriel Sandika Pareira  4 , Seiji Yamada  5 , Masahiro Joko  2 , Shunsuke Nakae  2 , Jun Muto  2 , Yuya Nishiyama  2 , Kazuhide Adachi  2 , Hikaru Sasaki  6 , Masato Abe  7 , Mitsuhiro Hasegawa  2 , Yuichi Hirose  2
Affiliations

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy

Shigeo Ohba et al. Sci Rep. .

Abstract

Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.

Keywords: Glioblastoma; Karnofsky Performance Status; MGMT; Radiotherapy; Temozolomide; Tumor size.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Fujita Health University (Approval No. HM22-434).

Figures

Fig. 1
Fig. 1
Patient selection flow chart. RT, radiotherapy, TMZ, temozolomide.
Fig. 2
Fig. 2
(a) Progression-free survival, (b) overall survival, and (c) survival time with maintenance of KPS ≥ 50%.
Fig. 3
Fig. 3
Survival time with maintenance of KPS ≥ 50% using the preoperative KPS cutoff value of (a) 90%, (b) 80%, and (c) 70%.
Fig. 4
Fig. 4
Survival time with maintenance of KPS ≥ 50% using KPS cutoff value at the start of RT of (a) 90%, (b) 80%, and (c) 70%.
Fig. 5
Fig. 5
(a) The survival time with maintenance of KPS ≥ 50% in patients with residual tumor size ≥ 2 cm3 versus < 2 cm3. (b) The survival time with maintenance of KPS ≥ 50% in patients with methylated MGMT promoter versus those with unmethylated MGMT promoter. (c) The survival time with maintenance of KPS ≥ 50% in patients treated with BCNU wafer versus those not treated with BCNU wafer. The median survival time with maintaining KPS ≥ 50 for each group is provided in Table 2.
Fig. 6
Fig. 6
The survival time with maintenance of KPS ≥ 50% in patients with none, one, two, or all three favorable factors (KPS at the start of RT ≥ 80%, methylated MGMT promotor, and residual tumor size < 2 cm3).
See this image and copyright information in PMC

References

    1. Reni, M., Mazza, E., Zanon, S., Gatta, G. & Vecht, C. J. Central nervous system gliomas. Crit. Rev. Oncol. Hematol.113, 213–234 (2017). - PubMed
    1. Ohba, S. & Hirose, Y. Current and future drug treatments for glioblastomas. Curr. Med. Chem.23, 4309–4316 (2016). - PubMed
    1. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med.370, 709–722 (2014). - PubMed
    1. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med.370, 699–708 (2014). - PMC - PubMed
    1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005). - PubMed

MeSH terms